

## DAFTAR ISI

<b>HALAMAN JUDUL</b> .....	i
<b>PERNYATAAN KEASLIAN KARYA TUGAS AKHIR</b> .....	ii
<b>PERSETUJUAN DOSEN PEMBIMBING TUGAS AKHIR</b> .....	iii
<b>PERSETUJUAN TIM PENGUJI TUGAS AKHIR</b> .....	iv
<b>ABSTRAK</b> .....	v
<b>ABSTRACT</b> .....	vi
<b>KATA PENGANTAR</b> .....	vii
<b>DAFTAR BAGAN</b> .....	xii
<b>DAFTAR TABEL</b> .....	xiii
<b>DAFTAR SINGKATAN</b> .....	xiv
<b>BAB I</b> .....	1
<b>PENDAHULUAN</b> .....	1
1. 1 Latar Belakang .....	1
1. 2 Rumusan Masalah .....	2
1. 3 Pertanyaan Penelitian .....	2
1. 4 Tujuan Penelitian .....	2
1. 5. 1 Tujuan Umum .....	2
1. 5. 2 Tujuan Khusus .....	2
1. 5 Manfaat Penelitian .....	2
1. 5. 3 Manfaat Penelitian Akademik .....	3
1. 5. 4 Manfaat Penelitian Praktis .....	3
<b>BAB II</b> .....	4
<b>TINJAUAN PUSTAKA</b> .....	4
2. 1. Tumor Otak Sekunder .....	4
2. 1. 1. Definisi .....	4
2. 1. 2. Epidemiologi .....	4
2. 1. 3. Patofisiologi .....	5
2. 1. 4. Terapi .....	8
2. 2. Gamma Knife .....	10
2. 2. 1. Sejarah Penemuan <i>Gamma Knife</i> .....	10

2. 2. 2. Mekanisme Kerja <i>Gamma Knife</i> .....	10
2. 2. 3. Faktor-Faktor yang Mempengaruhi Respons Terapi <i>Gamma Knife</i> Terhadap Tumor Otak Sekunder.....	11
2. 3. <i>Neutrophil-Lymphocyte Ratio</i> (NLR).....	12
2. 3. 1. Definisi.....	12
2. 3. 2. Nilai NLR Sebagai Faktor Prognosis untuk Tumor.....	12
2. 3. 3. Faktor-Faktor yang Mempengaruhi Nilai NLR .....	13
<b>BAB III</b> .....	15
<b>KERANGKA TEORI, KERANGKA KONSEP DAN HIPOTESIS</b> .....	15
3. 1. Kerangka Teori.....	15
3. 2. Kerangka Konsep .....	15
3. 3. Hipotesis Penelitian.....	15
3. 4. Variabel Penelitian .....	16
3. 5. Definisi Operasional.....	16
<b>BAB IV</b> .....	19
<b>METODOLOGI PENELITIAN</b> .....	19
4. 1. Desain Penelitian.....	19
4. 2. Lokasi Penelitian .....	19
4. 3. Bahan dan Cara Penelitian.....	19
4. 3. 1. Bahan.....	19
4. 3. 2. Cara Pengambilan Data.....	19
4. 4. Populasi dan Sampel Penelitian.....	19
4. 4. 1. Populasi Target.....	19
4. 4. 2. Populasi Terjangkau.....	19
4. 4. 3. Sampel Penelitian.....	19
4. 4. 4. Kriteria Penelitian .....	20
4. 5. Teknik Pengambilan Sampel.....	20
4. 6. Besar Sampel.....	20
4. 7. Pengolahan Data.....	21
4. 8. Uji Statistik.....	21
4. 9. Alur Penelitian.....	21




## DAFTAR BAGAN

Bagan 1. Proses metastasis tumor ke otak menjadi tumor otak sekunder.....	5
Bagan 2. Kerangka Teori .....	15
Bagan 3. Kerangka Konsep.....	15
Bagan 4. Alur Penelitian .....	21
Bagan 5. Alur Pemilihan Data Rekam Medis .....	23
Bagan 6. Kurva ROC .....	24



## DAFTAR TABEL

Tabel 1. Perubahan Gen dari Setiap Kanker Primer Bermetastasis ke Otak <sup>14</sup> .....	8
Tabel 2. Definisi Operasional .....	16
Tabel 3. Dana Penelitian .....	22
Tabel 4. Jadwal Penelitian.....	22
Tabel 5. Deskripsi klinikopatologis pasien (*continuity correction ; ** fisher's exact ; ***pearson chi square).....	23
Tabel 6. Hasil Uji Statistik Hubungan NLR dengan Respons Terapi Gamma Knife .....	25
Tabel 7. Analisa Multivariat Faktor-Faktor yang Mempengaruhi Respons Baik Terapi Gamma Knife.....	25



## DAFTAR SINGKATAN



WBRT	: <i>Whole Brain Radiation Therapy</i>
NLR	: <i>Neutrophil-Lymphocyte Ratio</i>
NINCDS	: <i>National Institute of Neurological and Communicative Disorders and Stroke</i>
SEER	: <i>Surveillance, Epidemiology, and End Results</i>
MDCSS	: <i>Metropolitan Detroit Cancer Surveillance System</i>
BBB	: <i>Blood-Brain Barrier</i>
C3	: <i>Complement Component 3</i>
COX2	: <i>Cyclooxygenase-2</i>
HBEGF	: <i>Heparin Binding EGF Like Growth Factor</i>
VEGF	: <i>Vascular Endothelial Growth Factor</i>
MMP9	: <i>Matrix Metalloproteinase 9</i>
BTB	: <i>Brain-Tumor Barrier</i>
ZOI	: <i>Zona Ocludens 1</i>
VE-CAM	: <i>Vascular Endothelial Cell Adhesion Molecule</i>
SOX2	: <i>SRY-Box Transcription Factor 2</i>
SOX9	: <i>SRY-Box Transcription Factor 9</i>
IL-6	: <i>Interleukin 6</i>
IL-8	: <i>Interleukin 8</i>
IFN $\alpha$	: <i>Interferon-<math>\alpha</math></i>
TNF	: <i>Tumor Necrosis Factors</i>
EGFR	: <i>epidermal growth factor receptor</i>
KRAS	: <i>Kirsten rat sarcoma virus</i>
LKB1	: <i>Liver Kinase B1</i>
AKT1	: <i>Protein Kinase B</i>
ATAD2	: <i>ATPase Family AAA Domain Containing 2</i>
BRAF	: <i>B-Raf</i>
DERL1	: <i>Derlin 1</i>
DNMT3B	: <i>DNA Methyltransferase 3 Beta</i>
KRT5	: <i>Keratin 5</i>



MYC	: <i>MYC Proto-Oncogene, BHLH Transcription Factor</i>
PROM1	: <i>Prominin-1</i>
NEK2A	: <i>NIMA-related kinases 2A</i>
NES	: <i>Nestin</i>
ATM	: <i>Ataxia-Telangiesctasia Mutated</i>
CDKN2A	: <i>Cyclin Dependent Kinase Inhibitor 2A</i>
CDKN2B	: <i>Cyclin Dependent Kinase Inhibitor 2B</i>
CRYAB	: <i>Crystallin Alpha B</i>
HSPB2	: <i>Heat Shock Protein Family B</i>
PTEN	: <i>Phosphatase and Tensin Homolog</i>
CDH13	: <i>Cadherin 13</i>
PLEKHA5	: <i>Pleckstrin Homology Domain Containing A5</i>
NRAS	: <i>Neuroblastoma RAS Viral Oncogene Homolog</i>
PIK3CA	: <i>Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit</i>
<i>Alpha</i>	
SRS	: <i>Stereotactic Radiosurgery</i>
Gy	: <i>Gray</i>
HER2	: <i>Human Epidermal Growth Factor Receptor 2</i>
RPA	: <i>Recursive Partitioning Analysis</i>
RTOG	: <i>Radiation Therapy Oncology Group</i>
KPS	: <i>Karnofsky Performance Status</i>
GPA	: <i>Graded Prognostic Assessment</i>
G-CSF	: <i>Granulocyte Colony-Stimulating Factors</i>
TGF- $\beta$	: <i>Transforming Growth Factor-Beta</i>
SHLV	: <i>Siloam Hospital Lippo Village</i>
MRI	: <i>Magnetic Resonance Imaging</i>
ROC	: <i>Receiver Operating Characteristics</i>
OR	: <i>Odds Ratio</i>